(0.25%) 5 144.50 points
(0.26%) 38 542 points
(0.37%) 17 911 points
(-0.74%) $83.23
(1.72%) $1.956
(-0.10%) $2 344.80
(1.28%) $27.60
(0.68%) $928.40
(-0.22%) $0.933
(-0.16%) $11.01
(-0.31%) $0.798
(0.78%) $92.59
0.50% INR 6 283.50
Live Chart Being Loaded With Signals
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments...
Stats | |
---|---|
Tagesvolumen | 107 350 |
Durchschnittsvolumen | 385 560 |
Marktkapitalisierung | 1 046.29B |
EPS | INR0 ( 2024-01-29 ) |
Nächstes Ertragsdatum | ( INR73.29 ) 2024-05-06 |
Last Dividend | INR40.00 ( 2023-07-11 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 20.06 |
ATR14 | INR3.24 (0.05%) |
Volumen Korrelation
Dr. Reddy's Laboratories Korrelation
10 Am meisten positiv korreliert | |
---|---|
SETF10GILT.NS | 0.933 |
ASHIANA.NS | 0.919 |
MOGSEC.NS | 0.915 |
ADORWELD.NS | 0.905 |
BHARATWIRE.NS | 0.903 |
IZMO.NS | 0.898 |
BAJAJ-AUTO.NS | 0.893 |
GTNTEX.NS | 0.884 |
CYIENT.NS | 0.883 |
MASPTOP50.NS | 0.882 |
10 Am meisten negativ korreliert | |
---|---|
STARTECK.NS | -0.898 |
SUNCLAYLTD.NS | -0.875 |
SCI.NS | -0.87 |
TEAMLEASE.NS | -0.856 |
ORTINLAB.NS | -0.853 |
MOHOTAIND.NS | -0.851 |
EASTSILK.NS | -0.851 |
ROLTA.NS | -0.844 |
CLNINDIA.NS | -0.844 |
GENESYS.NS | -0.839 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Dr. Reddy's Laboratories Korrelation - Währung/Rohstoff
Dr. Reddy's Laboratories Finanzdaten
Annual | 2022 |
Umsatz: | INR245.88B |
Bruttogewinn: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Umsatz: | INR245.88B |
Bruttogewinn: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Umsatz: | INR214.39B |
Bruttogewinn: | INR113.84B (53.10 %) |
EPS: | INR142.08 |
FY | 2021 |
Umsatz: | INR189.72B |
Bruttogewinn: | INR103.08B (54.33 %) |
EPS: | INR103.94 |
Financial Reports:
No articles found.
Dr. Reddy's Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR60.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR40.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR2.50 | 2003-08-08 |
Last Dividend | INR40.00 | 2023-07-11 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | INR363.00 | -- |
Avg. Dividend % Per Year | 0.62% | -- |
Score | 3.63 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.28 | |
Div. Directional Score | 8.85 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR40.00 | 1.93% |
2019 | INR20.00 | 0.77% |
2020 | INR25.00 | 0.87% |
2021 | INR25.00 | 0.48% |
2022 | INR60.00 | 1.24% |
2023 | INR40.00 | 0.94% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TNPETRO.NS | Dividend Junior | 2023-09-18 | Sporadic | 23 | 2.02% | |
PFIZER.NS | Dividend Junior | 2023-08-11 | Annually | 22 | 0.82% | |
JAYBARMARU.NS | Dividend Junior | 2023-09-08 | Annually | 23 | 1.48% | |
DCMSHRIRAM.NS | Dividend Junior | 2023-07-18 | Semi-Annually | 23 | 1.23% | |
SIYSIL.NS | Dividend Junior | 2023-07-24 | Semi-Annually | 18 | 1.37% | |
MEDICAMEQ.NS | Ex Dividend Junior | 2023-09-20 | Annually | 3 | 0.02% | |
GULFOILLUB.NS | Dividend Junior | 2023-08-25 | Annually | 11 | 2.19% | |
BBTC.NS | Dividend Junior | 2023-09-22 | Annually | 22 | 0.08% | |
PRESTIGE.NS | Dividend Junior | 2023-09-14 | Annually | 14 | 0.25% | |
KANSAINER.NS | Dividend Junior | 2023-05-25 | Annually | 21 | 0.49% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.192 | 1.500 | 6.15 | 9.23 | [0 - 0.5] |
returnOnAssetsTTM | 0.140 | 1.200 | 5.33 | 6.40 | [0 - 0.3] |
returnOnEquityTTM | 0.209 | 1.500 | 8.79 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.127 | -1.000 | 8.73 | -8.73 | [0 - 1] |
currentRatioTTM | 2.55 | 0.800 | 2.26 | 1.809 | [1 - 3] |
quickRatioTTM | 1.800 | 0.800 | 4.12 | 3.30 | [0.8 - 2.5] |
cashRatioTTM | 0.0784 | 1.500 | -0.675 | -1.013 | [0.2 - 2] |
debtRatioTTM | 0.0532 | -1.500 | 9.11 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 44.26 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0741 | -1.500 | 9.70 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.641 | 1.000 | 2.66 | 2.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.240 | 1.000 | 7.20 | 7.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.70 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.728 | 0.800 | 8.48 | 6.79 | [0.5 - 2] |
Total Score | 11.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.94 | 1.000 | 8.09 | 0 | [1 - 100] |
returnOnEquityTTM | 0.209 | 2.50 | 9.22 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.640 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.127 | 1.500 | 8.73 | -8.73 | [0 - 1] |
pegRatioTTM | 0.219 | 1.500 | -1.873 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.198 | 1.000 | 7.56 | 0 | [0.1 - 0.5] |
Total Score | 6.28 |
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.